Skip to main content
. Author manuscript; available in PMC: 2012 Oct 15.
Published in final edited form as: Clin Cancer Res. 2009 Nov 24;15(23):7441–7446. doi: 10.1158/1078-0432.CCR-09-1361

Figure 1.

Figure 1

Systemic TM therapy protects against Her2/neu-induced mammary tumorigenesis. Nulliparous female 100-day old MMTV-Her2/neu mice were randomly assigned to two treatment groups and gavaged with water (control) or 0.75 mg/day TM for 180 days (n=15 for each group). At the end of the treatment protocol, control and TM-treated mice that did not develop mammary tumors were released from therapy and observed for the next 180 days. The disease-free survival curves for the two groups were compared using log rank analysis (p<0.0005).